Get the Stockscreener App
1.56
4.88%
-0.08
After Hours:
1.61
0.05
+3.21%
Mindwalk Holdings Corp stock is traded at $1.56, with a volume of 270.13K.
It is down -4.88% in the last 24 hours and up +21.88% over the past month.
MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
See More
Previous Close:
$1.64
Open:
$1.66
24h Volume:
270.13K
Relative Volume:
0.81
Market Cap:
$72.87M
Revenue:
$13.18M
Net Income/Loss:
$-9.65M
P/E Ratio:
-8.1933
EPS:
-0.1904
Net Cash Flow:
$-8.58M
1W Performance:
-7.14%
1M Performance:
+21.88%
6M Performance:
-11.86%
1Y Performance:
+0.00%
1-Day Range:
$1.56
$1.71
1-Week Range:
$1.538
$1.88
52-Week Range:
$0.99
$2.99
Mindwalk Holdings Corp Stock (HYFT) Company Profile
Compare HYFT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HYFT
Mindwalk Holdings Corp
|
1.56 | 76.61M | 13.18M | -9.65M | -8.58M | -0.1904 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.95B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.90B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 38.64B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 31.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mindwalk Holdings Corp Stock (HYFT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Oct-25-21 | Initiated | The Benchmark Company | Buy |
Mindwalk Holdings Corp Stock (HYFT) Latest News
MindWalk CEO to Join Jones AI Day Panel on Future of AI Drug Discovery - TipRanks
MindWalk (NASDAQ: HYFT) CEO joins Jones AI Day panel on AI drug discovery - Stock Titan
MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery - Yahoo Finance
HYFT Unveils ReefIQ for Enhanced AI Drug Discovery - GuruFocus
MindWalk Holdings Corp. Launches ReefIQ™ for AI-Driven Drug Disc - GuruFocus
MindWalk Holdings Unveils ReefIQ Context Layer to Power AI Drug Discovery - TipRanks
[6-K] MindWalk Holdings Corp. Current Report (Foreign Issuer) | HYFT SEC FilingForm 6-K - Stock Titan
MindWalk Holdings Corp. (NASDAQ: HYFT) Launches ReefIQ™, a Biological Context Layer for AI Drug Discovery - The Joplin Globe
HYFT Q1 2026 Earnings: EPS Falls Short of Estimates as Stock Gains 3.75%EPS Growth Report - newsline.com
Top MindWalk (HYFT) Competitors 2026 - MarketBeat
MindWalk (HYFT) Earnings Date and Reports 2026 - MarketBeat
MindWalk Showcases HYFT® Platform With Pan-Serotype Dengue Preclinical Data - TipRanks
MindWalk (NASDAQ: HYFT) reports HYFT AI preclinical dengue antibodies across all four serotypes - Stock Titan
MindWalk's HYFT Platform Shows Promising Preclinical Dengue Vacc - GuruFocus
MindWalk reports preclinical dengue vaccine data By Investing.com - Investing.com Nigeria
Bio-Native AI therapeutics MindWalk sets March 12 Q3 earnings call - Stock Titan
MindWalk reports preclinical dengue vaccine data - Investing.com
MindWalk's Preclinical Dengue Data Support a HYFT® Computational Prediction: Immunogens Designed on the Predicted Target Elicited Cross-Reactive Antibodies Against Antigens of All Four Dengue Serotypes, Reproduced Across Two Independent Camp - Business Wire
HYFT Q1 2026 Earnings: EPS Misses Estimates by 42.6%, Stock DeclinesOne-Time Gain Impact - thelegaladvocate.com
HYFT Q1 2026 Earnings: EPS Misses Estimates by 42.6%, Stock Declines 1.68%Share Dilution Risk - newsline.com
HYFT Q1 2026 Earnings: EPS Misses Estimates by 42.6% as Losses WidenGrowth Acceleration Report - The Legal Advocate
HYFT Q1 2026 Earnings: EPS Misses Estimates by a Wide 42.6% MarginProfit Inflection Point - newsline.com
MindWalk Stock Slips as AI Pandemic Platform Launch Puts HYFT Back in Focus - Bez Kabli
MindWalk Holdings Corp. (HYFT) Climbs 4.68%, Testing Key Resistance at $1.88Hot Stock Picks - The Legal Advocate
MindWalk (HYFT) Introduces Innovative Pandemic Response Platform - GuruFocus
MindWalk Holdings (HYFT) Climbs 4.91% as Buying Interest Builds Near Key SupportFast Moving Stocks - The Legal Advocate
MindWalk Company Profile & Introduction - Moomoo
MindWalk Holdings déploie une plateforme de réponse aux pandémies via la technologie HYFT® alors que les épidémies d'Ebola et d'hantavirus révèlent les limites de la couverture spécifique à chaque souche - Weekly Voice
MindWalk Holdings Corp. (HYFT) Launches Pandemic Response Platfo - GuruFocus
MindWalk Holdings Corp. (HYFT) Launches Pandemic Response Platform for Broad Protection - GuruFocus
MindWalk Holdings Deploys Pandemic Response Platform via HYFT® Technology as Ebola and Hantavirus Outbreaks Expose the Limits of Strain-Specific Coverage - 01net
MindWalk Holdings Launches AI-Driven Pandemic Response Platform for RNA Virus Outbreaks - TipRanks
MindWalk Holdings (NASDAQ: HYFT) unveils AI pandemic response platform for RNA viruses - Stock Titan
MindWalk Holdings Corp. (HYFT) Faces Selling Pressure as Price Approaches Key Support ZoneValue ETF - The Legal Advocate
MindWalk Holdings Leads Our Trio Of Promising Penny Stocks - simplywall.st
MindWalk’s Rebrand Turned A CRO Into An AI Platform Story - Finimize
MindWalk Holdings Corp.Common Stock (Nasdaq:HYFT) Stock Quote - The Chronicle-Journal
H.C. Wainwright reiterates MindWalk stock rating on platform validation - Investing.com
H.C. Wainwright reiterates MindWalk stock rating on platform validation By Investing.com - Investing.com Canada
HYFT Reiterated by HC Wainwright & Co. -- Price Target Maintained at $5.00 - GuruFocus
MindWalk (HYFT) Reports on Drug Candidates from Antibody Discove - GuruFocus
MindWalk Highlights 20-Plus Partner Drug Programs Tied to Its Discovery Platform - TipRanks
The Biology Came First. - Investing News Network
MindWalk (NASDAQ: HYFT) maps 20+ partner clinical programs and HYFT AI platform - Stock Titan
Mindwalk Holdings Corp Stock (HYFT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.04%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):